Molecular Partners AG

Molecular Partners AG is a biotechnology company focused on the discovery, development, and commercialization of a new class of custom-built protein therapeutics known as DARPins. These DARPins are designed to offer advantages over conventional antibody therapeutics, including multi-specific target binding, high potency, and cost-effective manufacturing. The company's research and development efforts are centered on creating innovative therapies for serious diseases across various therapeutic areas, including oncology and ophthalmology. Molecular Partners leverages its proprietary DARPin technology platform to generate a pipeline of potential drug candidates, aiming to address unmet medical needs and improve patient outcomes. As a biopharmaceutical company, Molecular Partners is committed to advancing scientific understanding and translating cutting-edge research into impactful treatments.